touchNEUROLOGY met with Richard Lipton (Albert Einstein College of Medicine, Bronx, NY, USA) to discuss the COURAGE study results investigating the Migraine Buddy Application.
The abstract ‘Combining UbRogepAnt and Preventives for MiGrainE (COURAGE) Study Using the Migraine Buddy Application: A Novel, Entirely Remote Design for Collecting Real-world Evidence’ was presented at the American Headache Society (AHS) Virtual Annual Scientific Meeting 2021, 3-6 June 2021.
Questions:
- Could you tell us a little about the unique design and methodology of the COURAGE study? (0:14)
- What have the interim study findings shown about the efficacy of ubrogepant when used in combination with a mAb or with onabotulinumtoxinA? (1:37)
- How do you anticipate use of the Migraine Buddy app developing in the future? (3:12)
Disclosures: Richard Lipton reports receives research support from the NIH, FDA as well as the National Headache Foundation and the Marx Foundation; and also receives research support from Allergan/Abbvie, Amgen, Eli Lilly and Electrocore. Richard Lipton receives personal fees as a consultant or advisor from from Allergan/Abbvie, Amgen, Biohaven Holdings, Dr. Reddy’s, GlaxoSmithKline, Grifols, Impel NeuroPharma, Novartis, Lundbeck, Merck, and Teva Pharmaceuticals; and holds stock or options in Biohaven Holdings and CtrlM Health.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of AHS Virtual Annual Scientific Meeting 2021.
